GMDA - Gamida Cell Ltd.
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.1000 |
| Open | 2.1200 |
| Bid | 2.1000 x 2900 |
| Ask | 2.1100 x 1300 |
| Day's Range | 2.0650 - 2.1300 |
| 52 Week Range | 0.5600 - 3.6600 |
| Volume | |
| Avg. Volume | 5,228,998 |
| Market Cap | 222.503M |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1900 |
| Earnings Date | May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.80 |
Fair Value
Related Research
Business WireGamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
BOSTON, May 31, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET.
Business WireData To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
BOSTON, May 31, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cell’s investigational natural killer (NK) cell therapy candidate GDA-201 will be shared at the International Society for Cell and Gene Therapy (ISCT) 2023 Annual Meeting. The meeting takes place May 31-June 3 in Paris, France.
Business WireGamida Cell Appoints Terry Coelho as CFO
BOSTON, May 22, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately. Shai Lankry, who has served as the company’s CFO for the past five years, is stepping down as CFO today and will leave the company June 2.
Simply Wall St.Breakeven On The Horizon For Gamida Cell Ltd. (NASDAQ:GMDA)
Gamida Cell Ltd. ( NASDAQ:GMDA ) is possibly approaching a major achievement in its business, so we would like to shine...
Business WireGamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
BOSTON, May 15, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended March 31, 2023.
Business WireGamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
BOSTON, May 11, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company.
- Simply Wall St.
Insiders who bought into Gamida Cell Ltd. (NASDAQ:GMDA) earlier this year might wish they'd invested more as stock gained 113%
Gamida Cell Ltd. ( NASDAQ:GMDA ) insiders who purchased shares in the last 12 months were richly rewarded last week...
Business WireGamida Cell Announces Pricing of $23 Million Public Offering of Securities
BOSTON, April 19, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share and accompanying warrant, for gross proceeds of approximately $22.8 million, before deducting underwriting discounts and commissions and estimated offering e
Business WireGamida Cell Announces Launch of Public Offering of Securities
BOSTON, April 18, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering and/or warrants to purchase its ordinary shares on the same terms and
ZacksGamida Cell (GMDA) Surges on FDA Approval for Omisirge
Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.
Business WireGamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
BOSTON, April 17, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv), for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the
Insider MonkeyGamida Cell Ltd. (NASDAQ:GMDA) Q4 2023 Earnings Call Transcript
Gamida Cell Ltd. (NASDAQ:GMDA) Q4 2023 Earnings Call Transcript March 27, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Gamida Cell’s Conference Call for the Full Year 2022 Financial Results. My name is Catherine and I’ll be your operator for today’s call. Please be advised that this call is being […]
American City Business JournalsIsraeli-Boston cell therapy firm lays off nearly one-fifth of workforce
An Israeli cell therapy company with a U.S. headquarters in Boston is laying off nearly one-fifth of its staff as it puts three drug programs aside.
Business WireGamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
BOSTON, March 27, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022. Net loss for 2022 was $79.4 million, compared to a net loss of $89.8 million in 2021. As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million.
Business WireGamida Cell Announces Changes to Board of Directors
BOSTON, March 20, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately.
Business WireGamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
BOSTON, March 20, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial results and provide an update on the company.
- Simply Wall St.
Gamida Cell Ltd.'s (NASDAQ:GMDA) largest shareholders are retail investors with 44% ownership, institutions own 29%
Key Insights The considerable ownership by retail investors in Gamida Cell indicates that they collectively have a...
Business WireGamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
BOSTON, March 07, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the upcoming Oppenheimer 33rd Annual Healthcare Conference on March 14th, 2023 at 9:20 a.m. ET.
Business WireData Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
BOSTON, February 18, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that two oral presentations and a poster presentation highlighting Gamida Cell’s investigational product candidates, omidubicel and GDA-201, were shared at the 2023 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT), and the Center for International Blood and Ma
ZacksGamida Cell (GMDA) Upgraded to Buy: Here's Why
Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
BOSTON, December 12, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, "Highbridge"). Pursuant to the loan agreement, Gamida Cell’s wholly-owned subsidiary, as borrower, will draw down $25 million from the fac
Business WireGamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
BOSTON, November 23, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences:
Business WireGamida Cell Provides Regulatory Update on Omidubicel
BOSTON, November 21, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration (FDA) relating to the company’s Biologics License Application (BLA) for omidubicel, the company’s advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant.
- Business Wire
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
BOSTON, November 14, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022. Net loss for the third quarter of 2022 was $17.8 million, compared to a net loss of $23.2 million in the third quarter of 2021. As of September 30, 2022, Gamida Cell had total cash, cash equivalents
Business WireGamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
BOSTON, November 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the Jefferies London Healthcare Conference, November 17, 2022 with a presentation at 9:10 a.m. GMT.